Research programme: skin disorders therapy - Wasatch
Alternative Names: Skin disorders therapy research programme - WasatchLatest Information Update: 18 Apr 2007
At a glance
- Originator Wasatch Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Skin disorders; Wounds
Most Recent Events
- 18 Apr 2007 Discontinued - Clinical-Phase-Unknown for Skin disorders in USA (unspecified route)
- 18 Apr 2007 Discontinued - Clinical-Phase-Unknown for Wounds in USA (unspecified route)
- 07 Aug 2001 New profile